A Clinical Trial to Evaluate the Bone Metabolism and the Blood Sugar of Evogliptin and Dapagliflozin

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 120 participants.

Also called NCT04706637

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 120 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT04706637
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT04706637. Randomized; no masking; primary purpose treatment. Start 2021-02-01 (anticipated); primary completion 2022-01-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Clinical Trial to Evaluate the Bone Metabolism and the Blood Sugar of Evogliptin and Dapagliflozin
Acronym
EVOMETA
Condition
Bone Diseases, Metabolic
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
Evogliptin
Intervention (Drug)
Dapagliflozin
Lead sponsor
Kyung Hee University Hospital at Gangdong (class: other)
Collaborator
Dong-A ST Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct04706637
Content hash
5592811afc2f72ddc3a66c1f0974bed5608576f3cc5fdcf2a67982b43c95a263